<DOC>
	<DOCNO>NCT00236691</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety topiramate add-on therapy patient difficult control partial onset seizure take one two standard antiepileptic drug .</brief_summary>
	<brief_title>A Study Efficacy Safety Topiramate add-on Therapy Treatment Epilepsy Patients With Difficult Treat , Partial-onset Seizures .</brief_title>
	<detailed_description>Epilepsy characterize seizure , abnormal electrical discharge brain temporarily disrupt normal brain function . Seizures classified `` generalize , '' originate side brain simultaneously , `` partial-onset , '' start one area brain . Antiepilepsy medication , topiramate , select base seizure type . This double-blind , placebo-controlled study evaluate efficacy safety topiramate add-on therapy patient refractory partial epilepsy , include baseline phase treatment phase difficult treat patient partial epilepsy . During baseline phase ( 12 week duration ) , patient receive one two follow standard antiepileptic drug ( AEDs ) : phenytoin , carbamazepine , phenobarbital , primidone , valproic acid . Patients continue seizure treatment standard AEDs proceed double-blind treatment phase . Patients receive placebo topiramate dosage 100-milligrams ( mg ) twice daily , increase twice daily dose maximum dose 600 mg/day , 800 mg/day , 1000 mg/day , maximum tolerate dose ( depend treatment group ) , Week 18 ( total duration double-blind phase ) , continue standard AED regimen . Assessments effectiveness include percent reduction average monthly seizure rate , percent patient respond treatment ( equal great 50 % reduction seizure rate ) , patient 's investigator 's global assessment medication end study . Safety assessment include incidence adverse event throughout study , clinical laboratory test ( hematology , serum chemistry , urinalysis ) , neurologic examination , vital sign measurement ( blood pressure , pulse , temperature ) weekly treatment phase . The study hypothesis topiramate , take add-on therapy treatment AEDs , significantly reduce seizure frequency , compare placebo , patient refractory partial epilepsy . In addition , hypothesize topiramate well-tolerated . Topiramate , 100 mg oral tablet , match placebo . Dosage begin 100-mg twice daily increase gradually twice daily dose maximum dose 600 , 800 , 1000 mg/day , continue Week 18 ( total duration ) .</detailed_description>
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsies , Partial</mesh_term>
	<mesh_term>Topiramate</mesh_term>
	<criteria>History simple complex partial epilepsy document witness 12week baseline phase , patient must least 12 partial seizure maintain therapeutic level antiepileptic drug ( AEDs ) one seizurefree interval 3 week none longer 3 week good physical health . Females capable child patient treatable cause seizure ( example , infection ) patient progressive disorder nervous system patient history status epilepticus ( repeat prolong seizure ) antiepileptic therapy history serious disease heart , liver , kidney , gastrointestinal , metabolic , endocrine system history alcohol drug abuse within one year prior study initiation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>topiramate</keyword>
	<keyword>epilepsy</keyword>
	<keyword>partial epilepsy</keyword>
	<keyword>partial epilepsy</keyword>
	<keyword>seizure</keyword>
	<keyword>epileptic seizure</keyword>
	<keyword>partial seizure disorder</keyword>
	<keyword>brain disease</keyword>
</DOC>